PDF herunterladen
Hamostaseologie 2019; 39(04): 398-403
DOI: 10.1055/s-0039-1691752
Case Report
Georg Thieme Verlag KG Stuttgart · New York

A Sardinian Family with Factor XI Deficiency

Doris Barcellona
1   Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
,
Giovanni Favuzzi
2   Atherosclerosis and Thrombosis Unit, IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
,
Maria Luigia Vannini
1   Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
,
Sebastiana Maria Piras
1   Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
,
Maria Filomena Ruberto
1   Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
,
Elvira Grandone
2   Atherosclerosis and Thrombosis Unit, IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
3   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moskva, Russia
,
Francesco Marongiu
1   Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

06. Januar 2019

12. April 2019

Publikationsdatum:
30. Juli 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction Factor XI (FXI) deficiency is a bleeding disorder which causes a bleeding tendency after trauma or surgery. An inhibitor may be acquired secondary to replacement therapy.

Aim To study on genetical and functional grounds a family admitted to our Haemostasis and Thrombosis Centre for an incidental finding of a prolonged activated partial thromboplastin time (aPTT) in three members.

Methods aPTT mixing test, dosage of FXI activity and antigen, FXI inhibitor titration, DNA analysis and clot waveform analysis (CWA) were performed.

Results Patients II.1, II.3 and II.4 showed a severe FXI deficiency (0.7, 0.7 and 1.8%, respectively) and low antigen level. Since the proposita was already treated with plasma, the dosage of the inhibitor was determined to be 6.4 Bethesda units. They were homozygous for the p.Glu117Stop mutation. The other family members were heterozygous. The velocity and the maximum acceleration of the clot formation were lower than those of the other family members and the normal subjects but higher than those of patients with acquired haemophilia A.

Conclusion A mixing test of a prolonged aPTT should be performed because it will be present both in patients with or without the inhibitor. A molecular analysis in severe FXI deficiency is warranted as it may have prognostic significance. CWA may be helpful for better understanding the pathophysiology of this kind of defect.

Keywords

factor XI deficiency - FXI inhibitor - bleeding - clot waveform analysis - aPTT
 

  • References

  • 1 Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82 (01) 171-174
    CrossrefPubMedGoogle Scholar
  • 2 Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol 2016; 9 (07) 629-637
    CrossrefPubMedGoogle Scholar
  • 3 Mumford AD, Ackroyd S, Alikhan R. , et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
    CrossrefPubMedGoogle Scholar
  • 4 Peretz H, Mulai A, Usher S. , et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood 1997; 90 (07) 2654-2659
    CrossrefPubMedGoogle Scholar
  • 5 Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A 1989; 86 (20) 7667-7671
    CrossrefPubMedGoogle Scholar
  • 6 Peretz H, Zivelin A, Usher S, Seligsohn U. A 14-bp deletion (codon 554 del AAGgtaacagagtg) at exon 14/intron N junction of the coagulation factor XI gene disrupts splicing and causes severe factor XI deficiency. Hum Mutat 1996; 8 (01) 77-78
    CrossrefPubMedGoogle Scholar
  • 7 Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 621-631
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 1999; 96 (03) 307-310
    CrossrefPubMedGoogle Scholar
  • 9 Soldà G, Asselta R, Ghiotto R, Tenchini ML, Castaman G, Duga S. A type II mutation (Glu117stop), induction of allele-specific mRNA degradation and factor XI deficiency. Haematologica 2005; 90 (12) 1716-1718
    PubMedGoogle Scholar
  • 10 Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12 (05) 490-493
    CrossrefPubMedGoogle Scholar
  • 11 Quélin F, Trossaërt M, Sigaud M, Mazancourt PD, Fressinaud E. Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost 2004; 2 (01) 71-76
    CrossrefPubMedGoogle Scholar
  • 12 Kasper CK, Aledort L, Aronson D. , et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (02) 612
    PubMedGoogle Scholar
  • 13 Braun PJ, Givens TB, Stead AG. , et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78 (03) 1079-1087
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 14 Shima M, Thachil J, Nair SC, Srivastava A. ; Scientific and Standardization Committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013; 11 (07) 1417-1420
    CrossrefPubMedGoogle Scholar
  • 15 Solano C, Zerafa P, Bird R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. Int J Lab Hematol 2011; 33 (01) 67-78
    CrossrefPubMedGoogle Scholar
  • 16 Margaglione M, Brancaccio V, Giuliani N. , et al. Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med 1998; 129 (02) 89-93
    CrossrefPubMedGoogle Scholar
  • 17 Tomaiuolo M, Favuzzi G, Cappucci F. , et al. Factor XI deficiency: two novel mutations in asymptomatic Italian patients. Haemophilia 2010; 16 (05) 767-770
    CrossrefPubMedGoogle Scholar
  • 18 Perani M. Gli ebrei in Sardegna fino al secolo VI: testimonianze storiche e archeologiche. La Rassegna Mensile Israel 1991; 57 (03) 305-344
    PubMedGoogle Scholar
  • 19 Castaman G, Giacomelli SH, Caccia S. , et al. The spectrum of factor XI deficiency in Italy. Haemophilia 2014; 20 (01) 106-113
    PubMedGoogle Scholar
  • 20 Teruya J, Styler M. Management of factor XI inhibitor for cardiac intervention: successful treatment with immunosuppressive therapy and plasma exchange. Haemophilia 2000; 6 (03) 158-161
    CrossrefPubMedGoogle Scholar
  • 21 Musclow CE, Amato D, Ofosu F, Armstrong AL, Abbott D. Transfusion-induced specific anti-factor XI inhibitor in a patient with previously unrecognized factor XI deficiency. Am J Clin Pathol 1988; 89 (03) 418-422
    CrossrefPubMedGoogle Scholar
  • 22 Schnall SF, Duffy TP, Clyne LP. Acquired factor XI inhibitors in congenitally deficient patients. Am J Hematol 1987; 26 (04) 323-328
    CrossrefPubMedGoogle Scholar
  • 23 Franchini M, Marano G, Mengoli C. , et al. Inhibitors in patients with congenital bleeding disorders other than hemophilia. Semin Thromb Hemost 2018; 44 (06) 595-603
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Livnat T, Tamarin I, Mor Y. , et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102 (03) 487-492
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 25 Salomon O, Zivelin A, Livnat T. , et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101 (12) 4783-4788
    CrossrefPubMedGoogle Scholar
  • 26 Margaglione M, Castaman G, Morfini M. , et al; AICE-Genetics Study Group. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93 (05) 722-728
    CrossrefPubMedGoogle Scholar
  • 27 Branchini A, Ferrarese M, Campioni M. , et al. Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations. Blood 2017; 129 (16) 2303-2307
    CrossrefPubMedGoogle Scholar
  • 28 Lawler P, White B, Pye S. , et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8 (02) 145-148
    CrossrefPubMedGoogle Scholar
  • 29 Alsammak MS, Ashrani AA, Winters JL, Pruthi RK. Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency. J Clin Apher 2017; 32 (06) 429-436
    CrossrefPubMedGoogle Scholar
  • 30 Ruberto MF, Sorbello O, Civolani A, Barcellona D, Demelia L, Marongiu F. Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena. Int J Lab Hematol 2017; 39 (04) 369-374
    CrossrefPubMedGoogle Scholar
  • 31 Ruberto MF, Marongiu F, Mandas A. , et al. The venous thromboembolic risk and the clot wave analysis: a useful relationship?. Clin Chem Lab Med 8; 56 (03) 448-453
    PubMedGoogle Scholar
  • 32 Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108 (05) 1447-1452
    CrossrefPubMedGoogle Scholar
  • 33 Jankowski M, Undas A, Kaczmarek P, Butenas S. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb Res 2011; 127 (03) 242-246
    CrossrefPubMedGoogle Scholar